{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Creatinine%2C+eGFR",
    "query": {
      "intervention": "Creatinine, eGFR"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Creatinine%2C+eGFR&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-19T20:29:02.057Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04181762",
      "title": "Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "secukinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 275,
      "start_date": "2020-07-07",
      "completion_date": "2023-09-13",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-09-19T20:29:02.057Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fontana",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04181762"
    },
    {
      "nct_id": "NCT05118074",
      "title": "Nova Max Creatinine and eGFR Meter System",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Diseases",
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Creatinine, eGFR",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Nova Biomedical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2021-06-08",
      "completion_date": "2024-04-15",
      "has_results": false,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-09-19T20:29:02.057Z",
      "location_count": 3,
      "location_summary": "Medley, Florida • Miami Gardens, Florida • Miami Lakes, Florida",
      "locations": [
        {
          "city": "Medley",
          "state": "Florida"
        },
        {
          "city": "Miami Gardens",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05118074"
    },
    {
      "nct_id": "NCT02320045",
      "title": "Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Insufficiency"
      ],
      "interventions": [
        {
          "name": "ITCA 650 (Exenatide in osmotic mini pump)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intarcia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "25 Years to 80 Years"
      },
      "enrollment_count": 38,
      "start_date": "2014-11",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-09-19T20:29:02.057Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02320045"
    },
    {
      "nct_id": "NCT04933747",
      "title": "Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Insufficiency"
      ],
      "interventions": [
        {
          "name": "Iberdomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "82 Years",
        "sex": "ALL",
        "summary": "18 Years to 82 Years"
      },
      "enrollment_count": 26,
      "start_date": "2021-08-12",
      "completion_date": "2023-01-23",
      "has_results": false,
      "last_update_posted_date": "2023-02-15",
      "last_synced_at": "2026-09-19T20:29:02.057Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Knoxville, Tennessee • San Antonio, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04933747"
    },
    {
      "nct_id": "NCT02059408",
      "title": "Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Screen-Educate",
          "type": "OTHER"
        },
        {
          "name": "Screen-Educate and Intensify Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1819,
      "start_date": "2015-09",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2020-01-07",
      "last_synced_at": "2026-09-19T20:29:02.057Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02059408"
    },
    {
      "nct_id": "NCT04340362",
      "title": "Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glomerulosclerosis, Focal Segmental"
      ],
      "interventions": [
        {
          "name": "VX-147",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2020-06-08",
      "completion_date": "2021-12-09",
      "has_results": true,
      "last_update_posted_date": "2025-09-24",
      "last_synced_at": "2026-09-19T20:29:02.057Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04340362"
    },
    {
      "nct_id": "NCT07734636",
      "title": "A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Early RASi restart strategy",
          "type": "DRUG"
        },
        {
          "name": "Usual Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-09-01",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-09-19T20:29:02.057Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07734636"
    },
    {
      "nct_id": "NCT04670926",
      "title": "Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Transplant Rejection",
        "Immunosuppression"
      ],
      "interventions": [
        {
          "name": "TruGraf",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Transplant Genomics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2021-06-03",
      "completion_date": "2023-09-30",
      "has_results": false,
      "last_update_posted_date": "2021-08-27",
      "last_synced_at": "2026-09-19T20:29:02.057Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04670926"
    },
    {
      "nct_id": "NCT06116253",
      "title": "Advanced Diffusion Imaging in Renal Cancer Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Renal Cancer"
      ],
      "interventions": [
        {
          "name": "Magnetic Resonance Imaging (MRI) Scan",
          "type": "DEVICE"
        },
        {
          "name": "Tc-99m Pentetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 39,
      "start_date": "2022-12-01",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-09-19T20:29:02.057Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06116253"
    },
    {
      "nct_id": "NCT01252810",
      "title": "Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Renal Insufficiency",
        "Diabete Mellitus",
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "GE-145",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 284,
      "start_date": "2010-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2018-08-29",
      "last_synced_at": "2026-09-19T20:29:02.057Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01252810"
    }
  ]
}